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Abstract
Background: Identifying the determinants of health-related quality of life (HRQOL) in patients with systolic heart
failure (CHF) is rare in primary care; studies often lack a defined sample, a comprehensive set of variables and clear
HRQOL outcomes. Our aim was to explore the impact of such a set of variables on generic and disease-specific
HRQOL.
Methods: In a cross-sectional study, we evaluated data from 318 eligible patients. HRQOL measures used were the
SF-36 (Physical/Mental Component Summary, PCS/MCS) and four domains of the KCCQ (Functional status, Quality
of life, Self efficacy, Social limitation). Potential determinants (instruments) included socio-demographical variables
(age, sex, socio-economic status: SES), clinical (e.g. NYHA class, LVEF, NT-proBNP levels, multimorbidity (CIRS-G)),
depression (PHQ-9), behavioural (EHFScBs and prescribing) and provider (e.g. list size of and number. of GPs in
practice) variables. We performed linear (mixed) regression modelling accounting for clustering.
Results: Patients were predominantly male (71.4%), had a mean age of 69.0 (SD: 10.4) years, 12.9% had major
depression, according to PHQ-9. Across the final regression models, eleven determinants explained 27% to 55% of
variance (frequency across models, lowest/highest b): Depression (6×, -0.3/-0.7); age (4×, -0.1/-0.2); multimorbidity
(4×, 0.1); list size (2×, -0.2); SES (2×, 0.1/0.2); and each of the following once: no. of GPs per practice, NYHA class,
COPD, history of CABG surgery, aldosterone antagonist medication and Self-care (0.1/-0.2/-0.2/0.1/-0.1/-0.2).
Conclusions: HRQOL was determined by a variety of established individual variables. Additionally the presence of
multimorbidity burden, behavioural (self-care) and provider determinants may influence clinicians in tailoring care
to individual patients and highlight future research priorities.
Background
Chronic systolic heart failure (CHF) is a common clini-
cal syndrome, with increasing incidence at older age,
and is associated with high mortality rates, and compro-
mised health-related quality of life (HRQOL) [1]. More-
over, it is characterised by a high health care utilisation
constituting a high burden of disease, mainly due to
hospital admissions [1].
The objectives of CHF treatment are to maximise life
expectancy, improve HRQOL and prevent disease pro-
gression and admissions [2]. Optimal treatment accord-
ing to clinical practice guidelines [2] and adherence of
patients to treatment regimens [3] are paramount.
Given the likelihood of poor prognosis, maximising
HRQOL is particularly important, especially as a sub-
stantial number of patients with CHF prioritize HRQOL
over survival [4,5] and patients’ perceptions of HRQOL
are used increasingly to evaluate the effectiveness of
healthcare interventions. Moreover, poorer HRQOL has
been shown to be predictive of higher admissions and
mortality [6,7].
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HRQOL is a multidimensional concept comprised of
several domains, including physical/biological factors,
symptom status, functional status, health perceptions,
and overall well-being [8]. In research, the use of generic
and disease-specific instruments to assess HRQOL is
recommended [9,10].
Many previous studies have deepened the understand-
ing about what factors can determine HRQOL in CHF,
not least to identify intervention targets for improved
outcome. They have been performed in various sectors
and settings, mostly in secondary care or post-discharge
setting [11-22], some in primary care [23-25] and few in
the community [26]. Variance of HRQOL has been asso-
ciated with sociodemographic (e.g. age, gender, socio-
economic status [16,18,19,23,25,26]), psychosocial (e.g.
depression, anxiety, social support [12,18-21,23-25]),
behavioural (e.g. alcohol consumption and smoking
[11,25]), clinical (e.g. disease severity assessed by NYHA
functional class or peakVO2, multimorbidity, BNP
[11,13-17,20-25]) and procedural (e.g. vasodilator use
[11]) determinants. Heterogeneity of results may be
explained by different settings and study designs (e.g.
part of a clinical trial or observational study [20,21,25] vs.
survey [16,23,24]) leading to heterogeneous samples (e.g.
younger patients with systolic HF vs. elderly with HF
with preserved systolic function), by different ‘availability
of variables’ and ‘use of instruments’ for generic vs. dis-
ease-specific HRQOL assessment.
Given there is little evidence for patients with CHF
recruited in primary care, our aim was to identify and
explore the impact of determinants of generic and disease-
specific HRQOL with respect to a wide set of individual
and provider variables. We focused on an exploratory
comparison between generic and disease-specific HRQOL.
Methods
Design
This study was conducted as a cross-sectional study of
pooled baseline data of subproject 10 “quality of life”
within the German “Competence Network Heart Fail-
ure”, sponsored by the Federal Ministry of Education and
Research [27]. Within this subproject two primary care-
based trials (TTT and HICMan) evaluated different kinds
of interventions [28-30]. Both trials conformed to the
principles outlined in the Declaration of Helsinki [31]
and were approved by the institutional review boards of
the local medical faculty of the university and the Medi-
cal Association of the federal state Baden-Württemberg
in Germany, and were registered (ISRCTN08601529 and
30822978) prior to inclusion of patients.
GP and patient selection
Interested GPs were eligible for participation if they
were certified as a primary care physician or equivalent
and practiced as a statutory health insurance affiliated
physician. Fifty general practitioners (GPs) from 48
practices participated in the two studies in one region of
Northern Baden, Germany.
Eligible patients were adults ≥ 40 years with confirmed
systolic heart failure (CHF) with stable symptoms at the
time of inclusion, and diagnosis of a chronic, irreversible
CHF at least 2 weeks prior to inclusion. CHF diagnosis
was based on dyspnea (NYHA) and objective measure-
ment (e.g. by echocardiography) of impaired left ventri-
cular systolic dysfunction (left ventricular ejection
fraction ≤ 45%). Criteria slightly differed between the
TTT-trial and HICMan-trial regarding the cut-off and
actuality of the determination of left ventricular ejection
fraction (TTT: ≤ 40% within last 6 months; HICMan:
≤ 45%, within the last 24 months) and dyspnea (TTT:
NYHA II-IV; HICMan: NYHA II-IV or NYHA I, if hos-
pital admission because of CHF within the last
24 months). Exclusion criteria were: Primary valvular
heart diseases and relevant hemodynamic effects, hyper-
trophic obstructive/restrictive cardiomyopathy (HOCM/
RCM), and people with a concomitant terminal illness,
addictive disorders (drug abuse or persisting alcohol
abuse despite social, legal or occupational conflicts),
dementia or severe psychological illness [28,30].
All GPs and patients gave written informed consent.
367 eligible patients were recruited, 168 within TTT
(enrolment of patients and data collection: March to
September 2005) and 199 within HICMan (enrolment of
patients and data collection: June 2006 to January 2007),
details have been described elsewhere [29,30]. Within
the HICMan-trial, two patients did not show up after
informed consent and 47 patients have participated in
the previous TTT-Trial. To obtain baseline data from
eligible patients “naive” of (the later tested) interven-
tions, we pooled baseline data of 318 patients (168+150).
Collection and management of Organisational and
Clinical data
GPs received an initiation visit by a study nurse includ-
ing an introduction to the trial’s investigator file. GPs
collected and documented organisational (location of
practice, list size, no. of GPs per practice, etc.), physi-
cians’ individual (e.g. years in practice) and patients’
individual clinical data (e.g. history, current clinical
status, lab results, ECG, detailed medication etc.) on
pre-specified case report forms (CRFs) according to the
Basic Clinical Dataset (BCD) of the Competence Net-
work Heart Failure [27]. The documentation of patients’
history included single co-occurring medical conditions
(such as Angina pectoris, Peripheral Arterial or Cerebro-
vascular Disease, Hypertension, Diabetes, COPD,
Depression etc.. For chronic care in primary care in gen-
eral, as for patients with CHF [32], the co-existence of
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multiple diseases is the rule rather than the exception
and therefore of special interest. Likewise, there is
co-existence of attempts to define the phenomenon of
co- and multimorbidity [33-37]: In one classification it
has been classified in three cumulative categories: simple
co-/multimorbidity (the co-occurrence of diseases,
whether coincidental or not); associative co-/multimor-
bidity (statistical association, not or not known to be
causal); and causal co-/multimorbidity (implying a cau-
sal relation among co-occurring diseases). Expanded
conceptualisations pay attention to „morbidity burden”
and „patient complexity” [38]: The former is linked to
its impact to patient-centred outcomes such as function-
ing and is therefore linked to the frailty construct. The
latter acknowledges socio-economic, cultural, beha-
vioural and environmental characteristics (see next para-
graph). These constructs address different aspects of
multimorbidity and are applied in three research areas
(clinical care, epidemiology and public health, and
health services research [38]. Accordingly, to retrieve an
estimate of patients’ “morbidity burden” in addition to
the documentation of single co-occurring medical con-
ditions, GPs applied the Cumulative Illness Rating Scale
(CIRS-G) [39-41]: This index measures the chronic
medical illness ("morbidity”) burden while taking into
consideration the severity of chronic diseases in 14
items representing individual body systems. The final
score of the CIRS is the sum of each of the 14 scores,
theoretically varying from 0 to 56, a higher score indi-
cating higher impairment. To determine N-terminal
Brain Natriuretic Peptide (NT-proBNP), blood was
taken separately for the Central Biomaterial Bank, a pro-
ject of the Competence Network Heart Failure providing
a central facility to collect all biomaterial (blood, plasma,
serum and DNA) from each patient enrolled in one of
the network’s clinical trials [42]. NT-proBNP was deter-
mined using the Elecsys 2010 Kit from Roche Diagnos-
tics, Germany. The CRFs were sent directly to the
responsible Coordination Centre Clinical Trials (CCCT).
Collection and management of Psychosocial and
Behavioural data
Parallel to the clinical baseline assessment, patient-
reported questionnaires were handed out by practice
personnel.
A sociodemographic dataset was obtained from all
patients [43]. For generic health-related quality of life
(HRQOL) we used the German version of the Short
Form 36 Health Survey (SF-36) [44] and for disease-spe-
cific HRQOL we used the German version of the Kansas
City Cardiomyopathy Questionnaire (KCCQ) [45], which
have been shown to be valid and reliable instruments
[45-47]. The SF-36 questionnaire consists of eight
dimensions (subscales): Physical functioning, Role
functioning (physical), Bodily pain, General health per-
ceptions, Vitality, Social functioning, Role functioning
(emotional), and Mental health. SF-36 scores are con-
verted to a (T-) scale of 0 to 100, with higher scores
indicating superior health status. Scales are aggregated
into two summary measures, the Physical Component
Summary (PCS) measure and the Mental Component
Summary (MCS) [48]. Empirical research showed that
scales that load highest on the PCS are most responsive
to treatments that change physical morbidity, whereas
scales loading highest on the MCS respond most to
drugs and therapies that target mental health [48]. The
KCCQ quantifies several health status domains includ-
ing Physical limitations, Symptoms (stability, frequency,
and burden), Self efficacy, (mental) Quality of life, and
Social function [45]. To summarise the multiple
domains of health status quantified by the KCCQ, a
clinical summary score (=Functional status, summarising
Physical limitations, Symptom frequency and burden)
can be calculated, whereas an overall summary score
(KCCQ-os) has been developed that includes Functional
status, Quality of life, and Social function domains, with
the exception of the domains Symptom stability and Self
efficacy. Each scale is transformed to a score of between
0 and 100, with higher scores indicating superior health
status. A mean five-point change (or difference) in the
scales of the SF-36 [49] and in the KCCQ-os [22,50] are
regarded as socially or clinically significant.
Depression was assessed using the German version of
the Patient Health Questionnaire depression module
(PHQ-9) [51]. It consists of 9 items that each describes
one symptom corresponding to one of the 9 DSM-IV
diagnostic criteria for major depressive disorder. The
use of continuous data in the form of the PHQ-9 sum-
mary score (0 to 27 points) indicate depression severity
(higher scores indicate higher severity) and a categorical
algorithm for major depressive syndrome in accordance
with DSM-IV diagnostic criteria can be calculated with
favourable diagnostic properties [51-53]. The PHQ-9
compares favourably to other screening instruments,
and is recommended for patients with cardiovascular
diseases [54].
The European Heart Failure Self-Care Behaviour Scale
(EHFScB scale) is a 12-item, self-administered question-
naire regarded as a valid, reliable and practical scale to
measure the self-reported self-care behaviour of heart
failure patients, for example, daily weighing, fluid
restriction, exercise or contacting a health care provider
[55]. Scores range from 1-5 (12-60), with low scores
implying better self-care behaviour. Patients were asked
to return the questionnaires in a pre-specified envelope
within seven days. Questionnaires were sent back to the
CCCT, where data management was performed [27] -
either directly (TTT) or via the study centre (HICMan)
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to enable the study nurse to monitor the progress of
study documentation.
Procedure and statistical methods
To allow comparisons across the two HRQOL measures
we decided a priori to focus on summary measures, i.e.
the PCS and MCS (SF-36), and Functional status, (men-
tal) Quality of life, Self efficacy and Social function
(KCCQ), all distinct domains that differentiate most ade-
quately between ‘physical’ and ‘psychosocial’ aspects of
HRQOL. Therefore, we omitted KCCQ-os as it repre-
sents aggregated scales of both aspects, rendering a com-
parison with generic HRQOL (PCS and MCS) difficult.
Our choice of variables to be analysed with respect to
their predictive value was based on the literature and
clinical reasoning. We selected variables of the provider
and individuals respectively as shown in tables 1 and 2.
Dummy variables were built for all ordinal variables
(location of practices, list size and no. of GPs per prac-
tice, patients’ socio-economic status, left ventricular
ejection fraction, Creatinin-Clearance). We aggregated
NYHA functional class I with II and II with IV account-
ing for the low number of observations in the classes I
and IV. As NT-proBNP had a skewed distribution, loga-
rithmic transformation was performed as described and
performed previously [25,56]. Alcohol consumption (no.
of drinks per week) was omitted because of skewed dis-
tribution not amenable to transformation.
Pearson correlation coefficients were calculated for
analyses of relationships between numerical explanatory
variables and the dependent variable. In the following,
Creatinin-clearance was omitted due to collinearity with
age, which correlated consistently higher with dependent
variables.
Variables with a p-value less than 0.05 were entered
into multiple regression analyses using the forward
selection algorithm. As this procedure uses only those
individuals who have complete information on all expla-
natory variables results were validated in unified regres-
sion models. All explanatory variables remained within
the models, except for NYHA functional class for PCS
and Hypertension for (mental) Quality of life (KCCQ).
To account for the clustering of data (intraclass correla-
tion within each practice attributable to clustering) we
performed linear mixed effects regression models with
the physician as a random effects model nested within
groups. Regression coefficients were the same; the few
exceptions regarding explanatory variables are reported.
Given the possibility to inform about the amount of
explained variance (R2) we present the results of the
unified regression models. For analyses we used Stata/
MP version 10.1, SPSS version 16.0.2 (SPSS Inc.) and
SAS 9.2 (PROC MIXED).
Results
Provider and patient characteristics
Table 1 shows the characteristics of 50 participating
GPs, with a mean age of 49.1 (SD: 9) and practicing on
average for 15 years (SD: 8.3) years. It also shows the
characteristics of the 48 participating practices (location,
Table 1 Characteristics of 50 general practitioners from 48 practices; values represent number (percentages) of
practices unless stated otherwise
Practice factors (n = 48)
Location
rural 25 (52.1)
suburban 10 (20.8)
urban 13 (27.1)
No. of GPs per practice
One GP 24 (50)
Two GPs 18 (37.5)
> 2 GPs 6 (12.5)
List size (patients per quarter)
0-999 11 (22.9)
1000-1499 18 (37.5)
≥1500 19 (39.6)
GPs’ characteristics (n = 50)
Mean age of in years (SD) [range] 49.1 (9.0) [33-63]
Female 11 (22)
Practicing as GP since mean years (SD) [range] 15.0 (8.3) [0-33]
Participation in trials (TTT only vs. HICMan only vs. TTT and HICMan) 20/13/17 (40/26/34)
Mean (SD; range) number of patients per GP 6.4 (4.8; 1-18)
GP: General practitioner
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number of GPs and patients per practice). The mean
(SD; range) number of patients per GP was 6.4 (4.8;
1-18).
Table 2 summarises the characteristics of 318 eligible
patients regarding socio-demographic, clinical, psychoso-
cial and behavioural variables. Patients were predomi-
nantly male (71.4%) with a mean age of 69 (SD: 10.4)
years and mostly belonging to the lower or middle social
class (36.3% and 42.5%). Most patients were in NYHA
functional class II or III (97%) and had a moderately
reduced LVEF (35.3 ± 7.2%). In 45% of the cases coronary
heart disease was the main cause for CHF as reported by
the treating GPs. Mean (SD) duration of CHF was 5.8
(5.1) years. Patients had undergone different cardiovascu-
lar interventions, 33% at minimum one PTCA and 22.6%
a CABG (coronary artery bypass graft) surgery. Vascular
medical conditions were prevalent, e.g. peripheral arterial
disease (17.3%), others were hypertension (78.9%), dia-
betes (36.5%), COPD (23.6%) and Depression (20.8%).
Estimated renal function was impaired in more than 40%
of cases (GFR < 60 ml/min). Mean (SD) NT-proBNP-
levels were 2298.4 (3985.9) pg/ml. Physician-rated mean
(SD) multimorbidity as indicated by CIRS-score was 23.8
(5.5). Mean (SD) summary PHQ-9 screening score was
Table 2 Patient characteristics (n = 318); values represent
numbers (percentages) of patients unless stated
otherwise
Trials source (participation in TTT- vs. HICMan-trial) 168/150 (52.8/
47.2)
Sociodemographic characteristics
Male sex 227 (71.4)
Mean (SD) age (years) 69.0 (10.4)
Social class*: (n = 277)
lower 117 (36.8)
middle 135 (42.5)
upper 25 (7.9)
Clinical variables
NYHA-functional class (according to GP)
I 4 (1.3)
II 185 (58.2)
III 124 (39.0)
IV 5 (1.6)
Mean (SD) LVEF (n = 304) 35.3 (7.2)
LVEF not reported 14 (4.4)
≤ 45% 221 (69.5)
≤ 30% 83 (26.1)
Main cause of CHF
ischemic 143 (45.0)
non-ischemic 175 (55.0)
Mean (SD) duration (years) of CHF (n = 238) 5.8 (5.1)
Cardiovascular interventions
PTCA/Stent (any) 105 (33.0)
CABG (any) 72 (22.6)
Pacemaker (right ventricular) 44 (13.8)
Pacemaker (biventricular) 19 (6.0)
ICD 49 (15.4)
Prosthetic heart valve (any) 20 (6.3)
Reanimation/Defibrillation 22 (6.9)
Medical conditions
Angina pectoris 81 (25.5)
PAD 55 (17.3)
Cerebrovascular disease 60 (18.9)
Hypertension 251 (78.9)
Diabetes mellitus 116 (36.5)
COPD 75 (23.6)
Depression (as rated by GP) 66 (20.8)
Creatinine-Clearance (n = 314): Mean (SD) GFR
(ml/min)**
71.2 (31.1)
Stage of renal dysfunction
GFR ≥ 60 ml/min 182 (57.2)
GFR 30-59 ml/min 119 (37.4)
GFR ≤ 29 ml/min 13 (4.0)
Mean level of NT-pro-BNP*** (SD) in pg/ml (n =
303)
2298.4 (3985.9)
Mean (SD) Comorbidity (CIRS-G)**** 23.8 (5.5)
Psychosocial and behavioural characteristics
Depression (PHQ-9-D)
Table 2 Patient characteristics (n = 318); values represent
numbers (percentages) of patients unless stated other-
wise (Continued)
Mean (SD) summary score 7.2 (5.4)
Major Depressive Syndrome 41 (12.9)
Mean number (SD) of drinks per week 4.2 (6.4)
Ex-/smoker (Ex: since at least 6 months) 142/46 (44.7/
14.5)
Heart failure self-care behaviour (EHFScB
scale*****)
24.7 (7.6)
Prescribed drugs
ACE inhibitor 243 (76.4)
A2RA 62 (19.5)
b-blocker 246 (77.4)
Spironolactone/Eplerenone (Aldosterone-
antagonists)
89 (28.0)
Loop diuretics 195 (61.3)
**Social Class according to modified German Winkler-index [43] (lower class:
0-7; middle class: 8-14; upper class: 15-21);
NYHA, New York Heart Association; LVEF, Left ventricular ejection fraction;
CHF, Chronic (systolic) heart failure; CHD, Coronary heart disease; PTCA,
Percutaneous Transluminal Coronary Angioplasty; CABG, Coronary artery
bypass graft surgery; ICD, Implantable cardioverter defibrillator; PAD,
Peripheral arterial disease; COPD, Chronic obstructive pulmonary disease;
**Estimation of the GFR according to the formula of Cockroft and Gault;
***N-terminal Brain Natriuretic Peptide;
****CIRS-G, Cumulative illness (physician) rating scale, range 0-56, lower scores
imply less impairment of 14 body systems
*****European Self-care Behaviour scale, range 12-60, lower scores imply
better self-care behaviour;
ACE = angiotensin converting enzyme; A2RA = angiotensin-2 receptor
antagonist
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7.2 (5.4), accordingly every 8th patient (12.9%) fulfilled
criteria for major depression. Every 7th patient was a
smoker; average alcohol consumption was 4.2 drinks per
week. Mean (SD) EHFScB scale score (Heart failure self-
care behaviour) was 24.7 (7.6).
Most patients were treated with ACE inhibitors or
angiotensin-2 receptor antagonists, b-blockers and many
with loop diuretics. 28% of the patients were prescribed
aldosterone antagonists.
Quality of life
Mean SF-36 scores (subscales and summary measures),
KCCQ domains and summary scores are shown in
Table 3, which shows that HRQOL was considerably
impaired in all SF-36 scales and KCCQ domains.
Determinants of health-related quality of life
Table S1 (see Additional file 1) summarises the results
of the final six regression models for generic, i.e. the
Physical and Mental Component Summary (PCS and
MCS), and disease-specific HRQOL, i.e. the KCCQ sum-
mary scale Functional status and the distinct domains
(mental) Quality of life, Self efficacy and Social limita-
tion (KCCQ). In these models, eleven determinants
overall explained between 27% and 55% of variance of
HRQOL.
Organisational (provider) variables, i.e. a greater
(patient) list size impacted negatively on the MCS and
Self efficacy, whereas a higher number of physicians per
practice determined MCS positively.
Among sociodemographic factors, age remained in
four of the overall six models (PCS, Functional Status,
Self efficacy and social limitation; b: -0.14 to -0.21), and
a higher socio-economic status in PCS and Self efficacy
(b: 0.14 to 0.23).
NYHA functional class contributed only to the
explained variance of the disease-specific summary scale
Functional Status (b: -0.16), whereas COPD for the gen-
eric summary PCS (b: -0.15).
A history of CABG surgery determined the generic
HRQOL summary MCS positively (b: 0.09) and the pre-
scription of an aldosterone antagonist the KCCQ
domain Social limitation negatively (b: -0.13). Aggre-
gated physician-rated multimorbidity (CIRS-G) contrib-
uted to the explained variance in generic and specific
scales (PCS, Functional status, (mental) Quality of life
and Social limitation; b: -0.09 to -0.14).
Better self-care behaviour (as measured by the
EHFScB scale) contributed significantly to the KCCQ
domain Self efficacy (b: -0.21).
Depression severity (PHQ-9 summary score) was a
significant determinant of generic and disease-specific
HRQOL in all models, and had the strongest impact
(b: -0.3 to -0.72) on each summary scale of HRQOL in
comparison to other determinants.
Discussion
Summary of main findings
In a clearly defined convenience sample of outpatients
with stable systolic chronic heart failure (CHF), we
could explore determinants of generic and disease-speci-
fic health-related quality of life (HRQOL) using a wide
set of explanatory variables. Generic and disease-specific
HRQOL varies but is considerably impaired in these
patients. They demonstrated good Heart failure self-care
behaviour but a considerable burden of (multi-)morbid-
ity. We explored the impact of sociodemographic vari-
ables, objective measures of heart failure severity,
somatic and depressive comorbidity, behavioural and
provider variables on the variance of generic and dis-
ease-specific HRQOL in patients with CHF using multi-
ple linear regression analyses. Eleven determinants were
independently associated with generic and/or disease-
specific HRQOL: These were depression severity, physi-
cian-rated morbidity burden, increasing age, bigger list
size, higher NYHA functional class, COPD, prescription
of aldosterone antagonist determined worse, whereas
more GPs (per practice), a higher socio-economic status,
better Self-care and history of CABG surgery deter-
mined better HRQOL.
Table 3 Generic and disease-specific mean (SD) quality of
life scores of patients
Quality of life measure Mean values (SD) No
SF-36 scales
physical functioning 49.0 (28.4) 318
role functioning, physical 38.7 (42.7) 280
bodily pain 61.2 (28.9) 316
general health perceptions 45.9 (19.0) 311
vitality 44.0 (22.5) 308
social functioning 70.6 (27.1) 317
role functioning, emotional 60.6 (46.3) 282
mental health 63.5 (21.9) 305
Physical Component Summary* 36.8 (10.3) 264
Mental Component Summary* 47.0 (11.9) 264
KCCQ domains
physical limitation 62.3 (24.8) 301
symptom stability 49.6 (16.1) 306
Symptoms 68.3 (24.1) 311
Functional status* 65.5 (22.4) 312
Self efficacy* 70.8 (23.0) 310
(Mental) Quality of life* 63.9 (26.0) 311
Social limitation* 63.9 (28.7) 297
Overall clinical summary 64.7 (22.6) 312
*Summary scales and distinct domains in bold represent target variables
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Findings and their relation to other studies
A considerable number of studies have led to conceptual
models of HRQOL in relation to CHF that describe the
interactive relationships between pathophysiology, symp-
toms (e.g. dyspnea, fatigue, ankle swelling), functional
and psychological aspects [57]. According to Rector,
people with CHF need to perceive symptoms - abnormal
states produced by the pathophysiology - before their
HRQOL is affected by CHF, either directly or indirectly.
The model acknowledges further the influence of other
exogenous factors, such as personality traits, lifestyle
demands, culture and multimorbidity that might alter
the apparent relationships.
Our results regarding the impact of objective measures
such as EF and BNP on HRQOL are similar to previous
literature: For example, while BNP correlated bivariately
with HRQOL scales, it did not remain in the multivari-
ate regression analyses with included (known) correlates
such as NYHA functional class. Therefore, decreased EF
or elevated BNP seems not to be sensed by the indivi-
dual, but the associated symptoms or functional status
[13,17].
Depression severity as assessed by the summary score
of the PHQ-9 had by far the greatest impact on
HRQOL variance in all six investigated summary scores
or domains, a finding that is in line with previous find-
ings: Gott et al. found depression, measured by a geria-
tric depression scale, determining generic and specific
HRQOL (summary scores of SF-36 and KCCQ) in a
cross-sectional study with 542 elderly (mean age 77
years) patients in primary care, a sample where the diag-
nosis of CHF was validated by the GP [23]. In our own
previous study, we found depression severity (measured
by PHQ-9) to be by far the strongest determinant of
subscales of SF-36 in a primary care-based sample of
167 patients (mean age 68 years) with ascertained systo-
lic HF [25].
In this study, NYHA functional class determined
KCCQ Functional Status, but not the Physical Compo-
nent summary of the SF-36. There, COPD, a disease
characterised also by ‘dyspnea’ was independently asso-
ciated. These findings are supportive for the higher spe-
cificity of the KCCQ than the SF-36 with regard to the
cardinal symptoms of CHF.
Moreover, our results regarding the role of disease
severity (NYHA class) and Depression (PHQ-9 summary
score) in disease-specific HRQOL (KCCQ) are in line
with Faller et al. [20]. They investigated the impact of
disease severity (represented by NYHA class) and
depression (represented by the categorical algorithm for
minor or major depression for the PHQ-9 score) in a
sample of 233 heart failure outpatients of a university
hospital (mean EF 43%, NYHA I/II/III in 15.9/39.5/
34.8% of patients). Disease severity and Depression
impacted on the full range of KCCQ domains and sum-
mary scores, while they found significant interaction in
the KCCQ domain (mental) Quality of life. The authors
discussed confounding due to the structural overlap
between the PHQ-9 and the quality of life domain of
the KCCQ, and biased patients’ perception in the sense
of over-reporting of subjective symptoms. In a consecu-
tive study entailing 206 subjects from the same sample,
by using structural equation techniques, Faller et al.
could determine the independent extent of impact of
disease severity and Depression on the domains (mental)
Quality of life and Physical limitation. They found that
depression influenced not only the psychological (ß =
0.75), but also the physical domain (ß = 0.3), whereas
heart failure severity, as measured by NYHA functional
class, affected the physical (ß = 0.44), but merely the
psychological (ß = 0.12) domain. Our results are at the
least coherent with these findings, as depression severity
impacted on KCCQ Functional status and (mental)
Quality of life, but heart failure severity (NYHA func-
tional class) only on Functional status, but not (mental)
Quality of life, even though Faller et al. chose the
KCCQ domain Physical limitation and used structural
equation techniques, which is more appropriate as it
allows for simultaneous analysis of the impact of multi-
ple explanatory variables on several dependent variables,
which was not the focus of our study.
Notably, physician-rated overall morbidity burden
(multimorbidity) was considerable (CIRS summary
score) and determined HRQOL in 4 of 6 investigated
models, i.e. in the PCS of the SF-36, but not MCS, and
in all KCCQ models, except for Self efficacy. Studies
that investigate co-/multi-morbidity in relation to
HRQOL of patients with CHF usually account for single
diseases and/or count the no. of conditions and rarely
used the CIRS instrument: We included the CIRS addi-
tionally to certain single conditions as a physician-rated
disease severity aggregate accounting for all body sys-
tems would better reflect the patients’ disease burden.
Regarding generic HRQOL, our results are consistent to
a study in primary care with a sample of 238 patients
with chronic diseases: The CIRS played a role within the
PCS (R2 0.18), but not within the MCS [58] and is in
line with empirical research that showed that scales that
load highest on the PCS are most responsive to treat-
ments that change physical morbidity, whereas scales
loading highest on the MCS respond most to drugs and
therapies that target mental health [48].
In a study with patients with CHF, the CIRS score
explained only a small part of the variance in one sub-
scale of the SF-36 - Bodily pain [25]. In this study, no
summary measures were analysed rendering a compari-
son across levels of aggregation difficult, but the differ-
ent extent of impact of multimorbidity on generic
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HRQOL is striking. Gott et al. could show the negative
impact of multimorbidity on generic and disease-specific
HRQOL, but multimorbidity was measured by counting
the number of conditions [23]. The impact of the
comorbidity COPD on PCS is congruent to Müller-
Tasch et al. and Franzén et al. who also found an
impact of respiratory diseases on the physical dimen-
sions of HRQOL [16,25]. The finding of history of
CABG surgery and its impact on the MCS of the SF-36
is difficult to interpret and should be replicated by
further studies. One might argue that a definitive ther-
apy with improved patient outcome regarding symptoms
(Angina pectoris) might impact also on generic aspects
of HRQOL. However, pectoral angina was not a signifi-
cant correlate in our study. We conclude that the role
found for multimorbidity (measured by CIRS) represents
appropriately the perspective of primary care, where
patients suffer from more than one index disease, and
balancing care and treatment together with the patient
is crucial. The CIRS measure seems the best available
for primary care [59], and an electronic version of the
instrument provides a practical application either for
clinical or research use [60], but future studies need to
clarify its value regarding HRQOL and prognosis in gen-
eral practice [61,62].
Socio-economic status (SES) impacted on KCCQ Self
efficacy and SF-36 PCS. Little is known regarding this
aspect in relation to CHF. In the study of Gott et al.
lower SES impacted negatively on MCS and KCCQ
overall scores [23], and education determined aspects of
HRQOL [11,15,26] or compliance [63], in patients with
heart failure. There is general knowledge that social
inequalities are associated with morbidity and mortality
[64,65], and also with health behaviour [66]. Our results
may add another additional finding that higher educated
people (SES) have lower levels of emotional and physical
distress, reduced by way of paid work and economic
resources, which are associated with high personal con-
trol [67].
A larger practice list size was associated with worse
HRQOL (MCS and Self efficacy), whereas a higher num-
ber of GPs per practice counterbalanced this observed
association (in MCS), which is a new finding, as there is
little evidence for the impact of organizational aspects, i.
e. practice factors, on HRQOL in CHF in routine care.
Moreover, our variables on organization (e.g. workload,
full-time equivalents, skill mix, degree of delegation, use
of chronic care services) were not comprehensive.
However, some literature on practice performance and
patient satisfaction shows associations within the organi-
zation of primary care that cannot be fully explained
[68-70]: In a cross-sectional study of 1188 general prac-
tices in The Netherlands, large practices showed no
clear association with higher assistant volumes and GPs’
workload; large practices had lower assistant volumes,
but more chronic care services [68]. In an observational
study of 140 practices across Europe [69], a larger prac-
tice size was associated with lower GPs’ workload, but
not chronic care organisation (according to the Chronic
Care Model). In a further study in 239 Dutch general
practices [70], van den Hombergh et al. found that GPs
providing more care time in the practice, and more time
per patient and experiencing less job stress are all asso-
ciated with patients’ perceptions of better care and
better practice performance. In the context of these
results, our finding would make sense. Thus, it warrants
consideration as a potential determinant of HRQOL,
while at the same time it needs to be replicated in
future studies together with a more complete set of
other explaining organisational variables.
The EHFScBS scores that aggregate the actual patient-
reported self-care behaviour (12 items) were associated
with KCCQ Self efficacy (2 items), as expected, although
the two instruments ask not completely the same con-
cepts: The instruments differ in that the EHFScBS asks
for patient’s agreement on defined 12 behaviours, and
the KCCQ Self efficacy asks about patient’s sureness on
what to do if heart failure worsens and about the
patient’s understanding of the ability to prevent worsen-
ing of CHF (for example, weighing yourself, eating a low
salt diet, etc.). According to the European Clinical Prac-
tice Guideline for CHF, HF self care can be defined as
action aimed at clinical stability, avoidance of behaviour
that can worsen the condition, and early detection of
symptoms of deterioration. Self care management is
regarded as a key issue of successful treatment and can
significantly impact on health outcomes [2]. According
to the author of a systematic review on self-care and
HRQOL in patients with CHF, findings from RCTs of
self-care, as an intervention, on HF patient HRQOL do
not allow strong conclusions about the benefits because
of methodological and conceptual issues [71]. The
author advocated large multi-site RCTs with self-care as
the primary intervention.
Limitations of the study
A number of limitations should be stated: The cross-
sectional design of our study implies that no cause-effect
relationship between variables can be established. The
explorative approach rather implies the identification of
independent associations, whereas predictive value needs
to be validated in consecutive studies. A known
dilemma exists between internal validity and generalisa-
bility: Participants of the parental trials might not be
representative for the population, e.g. because elderly
patients may decline to participate because of effort. On
the other hand, it can be regarded as strength - contrary
to most other studies in primary care - the sample
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consisted of patients with defined CHF, so more valid
statements can be made regarding this patient group.
Most complete models were obtained for KCCQ
Functional Status and (mental) Quality of life, whereas
most missings pertained to SF-36 summary scores,
socio-economic status and self-care. We abstained from
imputation methods as they have their own limitations.
We did not perform a non-responder analysis, but
regard our approach in the context of exploration as
appropriate.
Conclusions
Considerably impaired and varying health-related Quality
of life (HRQOL) of patients with systolic heart failure in
primary care could be explained by known determinants
in different patterns and to various extents across generic
and disease-specific concepts of HRQOL, such as age,
social status, depression symptoms and disease severity.
Patients’ perceptions of disease severity (depression and
functional decline) were the strongest determinants,
whereas, physician-rated multimorbidity (morbidity bur-
den) also impacts independently on HRQOL - more than
findings in previous studies suggest. New potentially rele-
vant variables, i.e. organisational aspects of primary care,
need to be confirmed in future studies. Our results also
corroborate the ongoing challenge of holistic care for
elderly (multimorbid) patients (with CHF) in primary
care. Information about patient and provider-related
determinants of HRQOL in patients with CHF may help
in providing individually tailored care.
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